PM360

DECEMBER 20, 2024

Swoop Launched in September 2024, the Swoop HCP Pro Suite is revolutionizing how pharmaceutical marketers engage with healthcare providers (HCPs). By tailoring messaging frequency and content to align with patient care journeys, marketers eliminate waste, improve engagement, and drive higher prescription lift.

Prescription 52

Prescription Healthcare Provider Insurance Marketing 52

Healthcare Success

JANUARY 2, 2024

Now that the holidays have drawn to a close, it’s time to return to your 2024 marketing plan and make adjustments that ensure your business is taking advantage of the latest trends in healthcare marketing to reach patients and HCPs more effectively and make a lasting impression.

Healthcare 78

Healthcare Healthcare Marketing Healthcare Provider 78

Pharmacy Times

MARCH 5, 2024

The continuous glucose monitoring system will be available for purchase online and without a prescription starting in summer 2024.

Prescription 59

Prescription FDA 59

PM360

DECEMBER 20, 2024

Pharmacies are also feeling the impact, as unaffordable medication costs lead to prescription abandonment, undermining long-term care plans. The State of Patient Access and Affordability A 2024 study 1 found that patients and providers both consider quick and accurate insurance verification their top priority.

Patients 52

Patients Prescription Retail Insurance 52

Pharmaceutical Technology

SEPTEMBER 3, 2024

New data provides more evidence on choosing the ideal approach for prescription of beta blockers for myocardial infarction.

Prescription 52

Prescription 52

PM360

MAY 23, 2024

For example, Bryan’s leadership played a pivotal role in the design and development of Veeva Compass’ modern data products—Veeva Compass Prescriber and National—featuring prescriber -and national- level projections based on both prescription and medical claims. As rare diseases affect about 1 in 10 people in the U.S.,

Retail 52

Retail Biopharma Prescription Healthcare Provider 52

PM360

FEBRUARY 8, 2024

Saatchi & Saatchi Wellness and TOM (Tikkun Olam Makers) The Prescription Paper Pill Bottle An innovative alternative to plastic, the Prescription Paper Pill Bottle is 100% compostable with no artificial glue and no toxic dye. It’s open-source design meets FDA requirements for safety and protection.

Prescription 52

Prescription Pharma Engineering Safety 52

PM360

NOVEMBER 13, 2023

When it comes to platforms used by HCPs to better understand prescription drug pricing information, GoodRx is second only to a provider’s electronic health record (EHR). Is GoodRx in Your 2024 HCP Marketing Plan? Click here to learn more about GoodRx HCP media solutions and give us a try in your 2024 HCP marketing plan.

Media 52

Media Prescription Healthcare Provider Patients 52

Pharmaceutical Commerce

JANUARY 24, 2024

The FDA assigned Autolus Therapeutics' biologics license application for obecabtagene autoleucel with a Prescription Drug User Fee Act date of November 16, 2024.

FDA 52

FDA Prescription 52

Pharmaceutical Commerce

NOVEMBER 4, 2024

With a 26% decline in prescription drug plans from 2024 to 2025, navigating potential gaps and accessing care remains vital for low income patients.

Prescription 52

Prescription Patients 52

PharmExec

FEBRUARY 21, 2024

The FDA assigned the biologics license application for linvoseltamab to treat relapsed/refractory multiple myeloma with a Prescription Drug User Fee Act of August 22, 2024.

FDA 52

FDA Prescription 52

Pharmaceutical Commerce

FEBRUARY 20, 2024

The FDA has assigned Servier’s New Drug Application for vorasidenib to treat IDH-mutant gliomas with a Prescription Drug User Fee Act action date of August 20, 2024.

FDA 52

FDA Prescription 52

Pharmaceutical Commerce

NOVEMBER 10, 2023

Blue Fin Group exec speaks on his upcoming feature.

Prescription 52

Prescription 52

Pharmacy Times

FEBRUARY 7, 2024

The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 8, 2024.

FDA 49

FDA Prescription 49

PharmExec

FEBRUARY 20, 2024

The FDA assigned the supplemental new drug application for Krazati (adagrasib) plus cetuximab in patients with locally advanced or metastatic colorectal cancer with a Prescription Drug User Fee Act goal date of June 21, 2024.

FDA 52

FDA Prescription Patients 52

PharmExec

FEBRUARY 6, 2024

The FDA assigned a Prescription Drug User Fee Act action date of June 7, 2024, to an application that would expand the indication of Arexvy to include adults 50-59 years with an increased risk of respiratory syncytial virus-related lower respiratory tract disease.

FDA 52

FDA Prescription 52

Nixon Gwilt Law

JANUARY 16, 2024

What can digital health innovators and investors anticipate for the industry in 2024? What can digital health innovators and investors anticipate for the industry in 2024? Read on to find out what else is on our Legal Vision Board for 2024! How is 2024 Shaping up for Your Business?

Healthcare 52

Healthcare Healthcare Management Insurance 52

Pharmaceutical Technology

JULY 28, 2022

Prescription of daily oral aripiprazole continues to dominate the use of Otsuka and Lundbeck’s once-monthly LAI formulation Abilify Maintena and Alkermes’ Aristada, which can be administered every six weeks. GlobalData forecasts that it will launch in the US and 5EU next year.

Prescription 98

Prescription Side effects Patients Management 98

European Pharmaceutical Review

OCTOBER 17, 2024

In August 2024, the European Commission approved EURneffy (adrenaline nasal spray) in the EU as the first needle-free emergency option to treat anaphylaxis. Poster Presented at the 2024 AAAAI Annual meeting, DC, US. This decision was granted a couple of weeks following approval by the US and Drug Administration (FDA).

Food and Drug Administration 121

Food and Drug Administration Medicine Consulting Food 121

Pharmaceutical Commerce

DECEMBER 19, 2023

Merck’s Biologics License Application for V116, a 21-valent pneumococcal conjugate vaccine, was given a Prescription Drug User Fee Act (PDUFA) date of June 17, 2024.

Prescription 52

Prescription FDA 52

Nixon Gwilt Law

JANUARY 16, 2024

What can digital health innovators and investors anticipate for the industry in 2024? Read on to find out what else is on our Legal Vision Board for 2024! Rebecca says, “ New and existing companies will offer GLP-1 prescriptions for weight loss. How is 2024 Shaping up for Your Business?

Healthcare 52

Healthcare Healthcare Management Insurance 52

PharmExec

DECEMBER 19, 2023

Merck’s Biologics License Application for V116, a novel 21-valent pneumococcal conjugate vaccine has been given a Prescription Drug User Fee Act (PDUFA) date of June 17, 2024.

Prescription 52

Prescription FDA 52

PharmExec

NOVEMBER 30, 2023

Supplemental new drug application for roflumilast cream 0.15% to treat atopic dermatitis in patients 6 years of age and older was assigned a Prescription Drug User Fee Act target action date of July 07, 2024.

Prescription 52

Prescription FDA Patients 52

PM360

SEPTEMBER 21, 2023

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. CMS will present an initial offer for each drug’s maximum fair price (MFP) by February 1, 2024.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

PM360

OCTOBER 22, 2024

Improving our collective understanding of the patient’s overall healthcare experience is necessary to effectively deliver prescription support. How can we ensure that vital prescription information reaches patients when they need it? 4 These statistics tell a story of trust, concern, and changing dynamics in healthcare communication.

Medical 52

Medical Patients Prescription Doctors 52

Nixon Gwilt Law

JUNE 24, 2024

The Digital Therapeutics Alliance Summit 2024 , held in Washington, D.C., Instead of limiting themselves under a prescription-based model, founders should explore alternative revenue streams. Collaborative ventures with school systems, employers, payers, and health systems are good opportunities to consider.

FDA 52

FDA Education Healthcare Provider Patients 52

Nixon Gwilt Law

JUNE 24, 2024

The Digital Therapeutics Alliance Summit 2024 , held in Washington, D.C., Instead of limiting themselves under a prescription-based model, founders should explore alternative revenue streams. Collaborative ventures with school systems, employers, payers, and health systems are good opportunities to consider.

FDA 52

FDA Education Healthcare Healthcare 52

PharmExec

FEBRUARY 20, 2024

The FDA set a Prescription Drug User Fee Act date during Q4 of 2024 for the biologics license application for datopotamab deruxtecan in patients with previously treated advanced nonsquamous non-small cell lung cancer.

FDA 40

FDA Prescription Patients 40

pharmaphorum

NOVEMBER 2, 2022

Around 70% of new prescriptions for the drug are for patients who haven’t received this type of therapy in the past, with fewer than 10% switching from Trulicity, said Lilly’s chief financial officer Anat Ashkenazi on the call.

Sales 105

Sales FDA Distribution Prescription 105

European Pharmaceutical Review

JULY 4, 2024

1 For use as prescription drugs, a botanical product must be approved by the FDA: to date, only two have gained this approval. The MA pathway is applicable for herbal medicines designed to treat more serious health conditions and require a medical prescription or the supervision of a medical practitioner. 2024 [cited 2024May].

Marketing 103

Marketing Food and Drug Administration Medicine Prescription 103

Pharmaceutical Technology

MAY 19, 2023

The prescription drug user fee act (PDUFA) date is expected to be set as January 2024. The new investigational therapeutic product candidate STS101 is a nasal powder formulation of dihydroergotamine mesylate (DHE), an anti-migraine drug, which is given through the company’s nasal delivery device.

Food and Drug Administration 59

Food and Drug Administration FDA Prescription Food 59

PM360

NOVEMBER 21, 2024

In Korlym’s 12th year on the market, the team was able to maximize the revised positioning, new campaigns, and new educational initiatives to increase new prescription demand by almost 50% and revenue by 39% (Q2 2024 vs. Q2 2023).*

Marketing 52

Marketing Education Prescription Pharmaceutical 52

PM360

MAY 21, 2024

Phreesia research shows that 25% of patients do not have a good understanding of the next steps around their prescription medications, and 29% aren’t sure how to manage their medical condition immediately following a healthcare visit.

Patients 52

Patients Prescription Side effects Doctors 52

Pharmaceutical Technology

JANUARY 6, 2023

The regulatory body has assigned a Prescription Drug User Fee Act (PDUFA) date for its decision in the third quarter of this year. If approved, nirsevimab will become the first single-dose preventative against RSV lower respiratory tract disease for the 2023/2024 RSV season in the US.

Food and Drug Administration 59

Food and Drug Administration FDA Prescription Food 59

Nixon Gwilt Law

JUNE 27, 2024

By name alone, “Food as Medicine” can be misunderstood as a treatment replacement for other medications or prescriptions. But the broader perception of FaM isn’t completely free from scrutiny by medical and public communities yet. Others have taken to calling it “Food as Health,” “Nutritional Therapy,” etc. to avoid confusion.

Food 40

Food Medicine Healthcare Healthcare 40

Nixon Gwilt Law

JUNE 27, 2024

By name alone, “Food as Medicine” can be misunderstood as a treatment replacement for other medications or prescriptions. But the broader perception of FaM isn’t completely free from scrutiny by medical and public communities yet. Others have taken to calling it “Food as Health,” “Nutritional Therapy,” etc. to avoid confusion.

Food 40

Food Medicine Healthcare Healthcare 40

Pharmaceutical Technology

JUNE 15, 2023

The regulator has set 13 February 2024 as a Prescription Drug User Fee Act goal date for the review of Ipsen’s sNDA. The Onivyde regimen comprises Onivyde (irinotecan liposome injection) along with 5-fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen).

Food and Drug Administration 52

Food and Drug Administration FDA Prescription Food 52